Quantcast
Last updated on April 21, 2014 at 12:45 EDT

Latest Thrombocytopenia Stories

2011-02-08 13:20:53

A Henry Ford Hospital study has found that a pharmacist-directed anticoagulation service improves the way medication is managed for patients with heparin-induced thrombocytopenia (HIT), a common but life-threatening thromboembolic disorder. Researchers found that patients treated by the anticoagulation service had a favorable response to alternative anticoagulant drugs three times faster and were 32 percent more likely to receive proper dosage than patients who were treated with the same...

2011-01-26 08:29:41

(Ivanhoe Newswire) -- Thrombotic thrombocytopenic purpura (TTP) is a potentially-fatal blood disorder that causes blood clots to form in small blood vessels that affect many organs including the liver, kidneys, heart, pancreas, and brain. Now, researchers have found a new and effective treatment for TTP. The current treatment is infusion of plasma, but it has been proven insufficient. A team of researchers, led by Jos© L³pez, at the Puget Sound Blood Center in Seattle, has generated...

2011-01-25 13:14:29

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease of the blood system. The condition is caused by the presence of ultralarge multimers of the protein von Willebrand factor, which promote the formation of blood clots (thrombi) in small blood vessels throughout the body. Current treatments are protracted and associated with complications. However, a team of researchers, led by Jos© L³pez, at the Puget Sound Blood Center, Seattle, has generated data in mice that...

2011-01-24 19:00:00

SHENYANG, China, Jan. 24, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or " Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has received official notification from China's State Food and Drug Administration ("SFDA") granting 3SBio manufacturing approval for a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura...

2011-01-24 14:42:00

RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. The Triad Group recall has been initiated due to concerns about potential microbial contamination of the alcohol products with Bacillus cereus that could potentially lead to life-threatening infections. Some of these alcohol prep pads...

2010-12-05 15:30:00

ORLANDO, Fla., Dec. 5, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The complete data,...

2010-12-02 15:18:00

THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of...

2010-11-22 19:11:34

Skin cells from humans can be revamped into pro-clotting cells called platelets, according to a study published on November 22 in the Journal of Experimental Medicine (www.jem.org). Patients with diseases causing thrombocytopenia"”platelet deficiency"”often require repeated transfusions with platelets obtained from healthy donors. But donor platelet isolation is expensive and labor intensive, and donor platelets can be attacked by the patient's immune systems as "foreign."...

2010-11-11 18:35:44

Study first to show that drug reduces risk of dangerous bleeding, need for spleen removal A new study finds that an FDA-approved drug to treat the rare autoimmune disorder immune thromobocytopenia (ITP) is more effective than earlier medical therapies in helping patients avoid surgical treatment and significantly improving their quality of life. The paper in the Nov. 11 New England Journal of Medicine reports that treatment with romiplostim, which mimics the effects of a growth factor that...

2010-11-10 16:04:00

THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from the first open-label study to compare Nplate(® )(romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need...